


PODOCYTE PUZZLES

Podocyte puzzle: IgA nephropathy

Joyita Bharati^{1,2}, Kiran Munir¹ and Kenar D. Jhaveri¹ 

¹Division of Kidney Diseases and Hypertension at Hofstra/Northwell and the Glomerular Center at Northwell Health, NY, USA and ²Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

The puzzle can be completed directly online in the supplementary data section.
Correspondence to: Kenar D. Jhaveri; E-mail: kjhaveri@northwell.edu



- 8 An oral targeted release formulation of steroids approved for treatment of IgA nephropathy (IgAN) (10)
- 9 Two complement pathways involved in IgAN are the alternate and ____ (6)
- 10 A major gastrointestinal (GI) source of abnormal IgA in IgAN (4)
- 11 The light chain that has an increased affinity with IgA in IgAN (6)

Down

- 1 The initial treatment of IgAN is with ____ months of steroids (3)
- 2 A GI disease associated with IgAN (6)
- 3 A surgical procedure that has limited data for treatment of IgAN in the non-Asian population (13)
- 4 Both BAFF and ____ promote B cell class switching of IgA producing plasma cells. (5)
- 5 Local ____ activation influences extent of glomerular damage in the kidney (10)
- 6 This anti-B cell agent has no role in treatment of IgAN (9)


Across

- 1 This acid in the IgA immune complexes makes them bind to mesangial cells stronger (6)
- 7 IgA1 molecule lacking terminal galactose units have increased affinity for extracellular matrix components and type IV collagen which will promote ____ deposition (9)

Received: 8.12.2022; Editorial decision: 20.3.2023

© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Answer key:



SUPPLEMENTARY DATA

Supplementary data are available at [ckj](#) online.

Received: 8.12.2022; Editorial decision: 20.3.2023

© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com